Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05533-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Anisha Jain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, JSS Science and Technology University, Mysuru, Karnataka, 570006, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Repositioning, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSS Academy of Higher Education and Research, Mysore.
Abstract (Originalsprache)
KRAS G12C-mutant non-small cell lung cancer (NSCLC) has transitioned from a therapeutically problematic disease to a precision-targetable cancer, anchored by the landmark approvals of sotorasib and adagrasib. Yet despite these advances, responses remain limited in duration and multiple mechanisms of rapid adaptive resistance emerge under inhibitor pressure. These resistance mechanisms define a therapeutic vulnerability map that can be addressed by repurposing approved agents with established safety profiles. This review emphasises the current understanding of KRAS G12C biology, integrates updated phase 3 clinical data and next-generation inhibitor pipelines through early 2026, and presents a mechanism-stratified drug repurposing framework that links validated bypass mechanisms to FDA-approved or clinically available compounds amenable to rapid combination trials. We further highlight patient-derived 3D models, multi-omics technologies, and ctDNA-guided monitoring as essential translational platforms. Finally, we propose an integrated translational roadmap that combines mechanistic insights with clinical innovation, offering new directions for precision therapy and improved patient outcomes in KRAS-driven NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, JSS Science and Technology University, Mysuru, Karnataka, 570006, India.
- Institute Germans Trias I Pujol, Badalona, Spain.
- Instituto Oncológico Dr Rosell (IOR), Hospital Universitari Dexeus, Barcelona, Spain.
- Department of Microbiology, JSS Academy of Higher Education and Research, Mysuru, Karnataka, 570015, India.
- Department of Anaesthesiology, KVC Super Speciality Hospital, Mysuru, Karnataka, 570004, India.
- School of Physical Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysuru, Karnataka, 570026, India.
Förderung
- JSS Academy of Higher Education and Research, Mysore
Zitieren
APA
Jain, A., Rosell, R., Dharmashekara, C., Shreevatsa, B., González-Cao, M., Shivakumar, A., Kollur, S. P., Prasad, A., Shivamallu, C., & Prasad, M. N. N. (2026). Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05533-0
Vancouver
Jain A, Rosell R, Dharmashekara C, Shreevatsa B, González-Cao M, Shivakumar A, et al. Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05533-0
BibTeX
@article{Jain2026,
author = {Jain, Anisha and Rosell, Rafael and Dharmashekara, Chandan and Shreevatsa, Bhargav and González-Cao, María and Shivakumar, Amogha and Kollur, Shiva Prasad and Prasad, Ashwini and Shivamallu, Chandan and Prasad, M N Nagendra},
title = {Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05533-0}
}
EUVIMED